GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02647944

CompletedPhase 2Results posted

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Lead sponsor

Mayo Clinic

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

•Healthy volunteers

Primary endpoint

•Gastric Emptying of Solids Half-time (T1/2)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02647944

Org study ID15-001783

Timeline

Milestones

Study start2015-12-18actual

Study first posted2016-01-06estimated

Primary completion2016-12-30actual

Study completion2016-12-30actual

Last update posted2017-10-27actual

Results first posted2017-10-27actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Overweight and obese adults (≥30 kg/m^2 or ≥27 kg/m^2 with an obesity-related co-morbidity).

•Subjects residing within 125 miles of Mayo Clinic in Rochester, Minnesota.

•Healthy individuals with no unstable psychiatric disease and not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, or endocrine (other than hyperglycemia type 2 diabetes mellitus on metformin) disorders.

•Women of childbearing potential will be using an effective form of contraception, and have negative pregnancy tests within 48 hours of enrolment and before each radiation exposure.

•Subjects must have the ability to provide informed consent before any trial-related activities.

Exclusion criteria

•Weight exceeding 137 kilograms (safety limit of camera for measuring gastric volumes).

•Abdominal surgery other than appendectomy, Caesarian section or tubal ligation.

•Positive history of chronic gastrointestinal diseases, systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat.

•Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia-type 2.

•Patients with a personal history of pancreatitis (acute or chronic)

•Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory, a self-administered alcoholism screening test (AUDIT-C), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by a Hospital Anxiety Depression (HAD) score >8 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.

•Intake of medication, whether prescribed or over the counter (except multivitamins), within 7 days of the study. Exceptions are birth control pill, estrogen replacement therapy, thyroxin replacement therapy and any medication administered for co-morbidities as long as they do not alter gastrointestinal motility including gastric emptying (GE) and gastric accommodation. For example, statins for hyperlipidemia, diuretics, β-adrenergic blockers,Angiotensin Converting Enzyme (ACE) inhibitors and angiotensin antagonists for hypertension, and metformin for type 2 diabetes mellitus or prediabetes are permissible. In contrast, resin sequestrants for hyperlipidemia [which may reduce GE and reduce appetite, α2-adrenergic agonists for hypertension, or other glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonists (exenatide) or amylin analogs (pramlintide) are not permissible because they significantly affect GE and/or gastric accommodation.

•Hypersensitivity to the study medication, liraglutide.

Endpoints (20)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Weight & body composition

Other (unclassified)

Weight & body composition

4 endpoints

Secondary/registry result

Weight Change at 5 Weeks

Time frame:baseline, 5 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (median), kg	95% CI
Liraglutide	3.70	2.80 – 4.80
Placebo	0.60	-0.30 – 1.4

p<0.001Wilcoxon (Mann-Whitney)

Secondary/registry result

Weight Change at 16 Weeks

Time frame:baseline, 16 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (median), kg	95% CI
Liraglutide	5.30	5.20 – 6.80
Placebo	2.5	0.1 – 4.2

p<0.001Wilcoxon (Mann-Whitney)

Secondary/protocol endpoint

Weight Change at 5 Weeks

Time frame:baseline, 5 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Weight Change at 16 Weeks

Time frame:baseline, 16 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Other clinical outcomes

14 endpoints

Primary/registry result

Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks

Time frame:5 weeks

descriptive

Posted result

Group	Value (median), minutes	95% CI
Liraglutide	180	162 – 295
Placebo	117	96 – 137

Primary/registry result

Gastric Emptying of Solids Half-time (T1/2) at 16 Weeks

Time frame:16 weeks

descriptive

Posted result

Group	Value (median), minutes	95% CI
Liraglutide	142	120 – 177
Placebo	113	101 – 133

Primary/protocol endpoint/low confidence

Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks

Time frame:5 weeks

descriptive

Primary/protocol endpoint

Gastric Emptying of Solids Half-time (T1/2) at 16 Weeks

Time frame:16 weeks

descriptive

Secondary/registry result

Satiety by Buffet Meal, Total Calories Ingested at 16 Weeks

Time frame:16 weeks

descriptive, improvement

Posted result

Group	Value (median), kcal	95% CI
Liraglutide	554.0	406 – 687
Placebo	680.5	513 – 1002

p0.27Wilcoxon (Mann-Whitney)

Secondary/registry result/low confidence

Satiation Volume to Fullness at 16 Weeks

Time frame:16 weeks

descriptive

Posted result

Group	Value (median), mL	95% CI
Liraglutide	360	360 – 600
Placebo	600	480 – 720

p0.069Wilcoxon (Mann-Whitney)

Secondary/registry result/low confidence

Satiation Maximum Tolerated Volume at 16 Weeks

Time frame:16 weeks

descriptive

Posted result

Group	Value (median), mL	95% CI
Liraglutide	750	651 – 908
Placebo	1126	944 – 1185

p0.054Wilcoxon (Mann-Whitney)

Secondary/registry result

Gastric Fasting Volume at 16 Weeks

Time frame:16 weeks

descriptive

Posted result

Group	Value (median), mL	95% CI
Liraglutide	231	192 – 277
Placebo	192	179 – 223

p0.13Wilcoxon (Mann-Whitney)

Secondary/registry result

Gastric Postprandial Volume at 16 Weeks

Time frame:16 weeks

change from baseline, descriptive

Posted result

Group	Value (median), mL	95% CI
Liraglutide	705	633 – 744
Placebo	668	605 – 794

p0.68Wilcoxon (Mann-Whitney)

Secondary/registry result

Gastric Accommodation Volume at 16 Weeks

Time frame:16 weeks (approximately 1 hour after 99mTC injection)

change from baseline, descriptive

Posted result

Group	Value (median), mL	95% CI
Liraglutide	453	378 – 536
Placebo	433	408 – 602

p0.95Wilcoxon (Mann-Whitney)

Secondary/protocol endpoint/low confidence

Satiety by Buffet Meal, Total Calories Ingested at 16 Weeks

Time frame:16 weeks

descriptive, improvement

Secondary/protocol endpoint

Satiation Volume to Fullness at 16 Weeks

Time frame:16 weeks

descriptive

Secondary/protocol endpoint/low confidence

Satiation Maximum Tolerated Volume at 16 Weeks

Time frame:16 weeks

descriptive

Secondary/protocol endpoint

Gastric Accommodation Volume at 16 Weeks

Time frame:16 weeks (approximately 1 hour after 99mTC injection)

change from baseline, improvement

Other (unclassified)

2 endpoints

Secondary/protocol endpoint

Gastric Fasting Volume at 16 Weeks

Time frame:16 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Gastric Postprandial Volume at 16 Weeks

Time frame:16 weeks

descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.
Obesity (Silver Spring, Md.)2022 Aug (month)PMID35894080doi:10.1002/oby.23481via clinicaltrials gov reference derived + pubmed nct search
GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
The Journal of clinical endocrinology and metabolism2020 May 1PMID31665455doi:10.1210/clinem/dgz140via clinicaltrials gov reference derived + pubmed nct search
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
The lancet. Gastroenterology & hepatology2017 Dec (month)PMID28958851doi:10.1016/S2468-1253(17)30285-6via CT.gov background + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.